Comments
Natco Pharma Ltd has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of Covid-19 positive patients.
“Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication,” Hyderabad based company said in a release.
“Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy,” it added.
Natco is hoping that CDSCO would give emergency approval of this drug based on “compassionate use” for patients.
“Compassionate use” approval is given for investigational drugs so a patient with an immediately life-threatening condition can gain access to the drug.
The company is ready to launch the product this month if approval is given.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.